

## 1. Company details

Name of entity:	Prescient Therapeutics Limited
ABN:	56 006 569 106
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

## 2. Results for announcement to the market

			\$
Interest revenue from ordinary activities	down	67.2% to	225,611
Loss from ordinary activities after tax attributable to the Owners of Prescient Therapeutics Limited	down	11.1% to	(7,322,531)
Loss for the year attributable to the Owners of Prescient Therapeutics Limited	down	11.1% to	(7,322,531)

### Dividends

There were no dividends paid, recommended or declared during the current financial period.

### Comments

The loss for the Consolidated entity after providing for income tax amounted to \$7,322,531 (30 June 2024: \$8,238,050).

### Financial performance

The Consolidated entity has recognised an estimated research and development ("R&D") tax incentive rebate for the year amounting to \$4,356,397 (2024: \$3,712,364) for eligible R&D expenses amounting to \$6,716,568 (2024: \$6,973,046) incurred during the year.

Corporate expenses decreased to \$931,588 (2024: \$998,430) and were primarily attributable to a decrease in professional fees paid for the year ended 30 June 2025.

Employment related expenses increased to \$3,719,499 (2024: \$2,434,455) and were primarily attributable to increase in consulting fee and share-based payment during the year ended 30 June 2025.

### Financial position

Net assets of \$11,387,172 (2024: \$18,067,288), primarily being cash and cash equivalents decreased during the year reflecting expenditure for R&D costs, corporate expenses and employment costs during the year.

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.21	2.04

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

## 6. Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

---

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

*Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements have been audited and an unmodified opinion has been issued.

---

## 11. Attachments

*Details of attachments (if any):*

The Annual Report of Prescient Therapeutics Limited for the year ended 30 June 2025 is attached.

---

## 12. Signed

A handwritten signature in black ink, appearing to be "J Campbell", written over a horizontal line.

Signed \_\_\_\_\_

Date: 20 August 2025

Dr James Campbell  
Chair

# Prescient Therapeutics Limited

ABN 56 006 569 106

Annual Report - 30 June 2025



**Prescient Therapeutics Limited**  
**Contents**  
**30 June 2025**



Corporate directory	2
Letter from the Chair	3
Directors' report	5
Auditor's independence declaration	22
Consolidated statement of profit or loss and other comprehensive income	23
Consolidated statement of financial position	24
Consolidated statement of changes in equity	25
Consolidated statement of cash flows	26
Notes to the consolidated financial statements	27
Consolidated entity disclosure statement	43
Directors' declaration	44
Independent auditor's report to the members of Prescient Therapeutics Limited	45
Shareholder information	49

Directors	Dr James Campbell, Chair (Appointed on 30 March 2025) Dr Allen Ebens, Non-Executive Director Dr Ellen Feigal, Non-Executive Director Dr Gavin Shepherd, Non-Executive Director (Appointed on 4 July 2024) Ms Melanie Farris, Non-Executive Director (Appointed on 10 April 2025)
Company Secretary	Ms Melanie Leydin
Registered office	Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Phone: 03 9692 7222
Principal place of business	Suite 2, Level 11, 385 Bourke Street Melbourne, VIC, 3000
Share registry	Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2010 Ph: 02 9698 5414
Auditor	William Buck Level 20, 181 William Street Melbourne, VIC 3000
Securities exchange listing	Prescient Therapeutics Limited securities are listed on the Australian Securities Exchange (ASX: PTX)
Website	<a href="https://ptxtherapeutics.com">https://ptxtherapeutics.com</a>

## **Letter from the Chair**

Dear Shareholders,

It is my pleasure to present the Prescient Therapeutics Annual Report for the financial year ended 30 June 2025. In this, my first year as Chair of Prescient, it is timely to reflect on the achievements of the past year, acknowledge the efforts of the outgoing CEO and Chair, and look forward to the anticipated growth and outcomes from the next exciting stage of our journey as a clinical stage biotechnology company.

### **Clinical Progress and Regulatory Momentum**

PTX-100, our lead candidate, continues to demonstrate its potential as a first-in-class targeted therapy, and the transition from Phase 1b to Phase 2a trials represents a significant strategic milestone. Following the encouraging Phase 1b results presented at global conferences, we opened our first Phase 2a clinical trial site in early 2025, a major milestone for the Company. The trial is focused on cutaneous T-cell lymphoma (CTCL), where PTX-100 has shown promising activity and a favourable safety profile. The Company continues to add new sites, and is pleased with enrolments to date.

Importantly, PTX-100 has now received Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation from the U.S. FDA for relapsed or refractory mycosis fungoides (CTCL). These regulatory designations not only validate the unmet need PTX-100 addresses but also open pathways for accelerated approval and market access in a US\$1.8 billion therapeutic space.

### **Cell Therapy Platforms: Innovation and Integration**

Our early-stage cell therapy platforms, CellPryme and OmniCAR, have potential niche applications, and we continue to discuss these with global academia and industry partners. CellPryme is being positioned as a potential transformative enhancement to existing CAR-T technologies, improving their durability and effectiveness. Meanwhile, OmniCAR's modularity and controllability potentially offer a differentiated approach to overcoming limitations in current cell therapies.

Prescient's reengineering efforts in OmniCAR have delivered marked improvements to earlier versions, and whilst the financial commitment needed to fund our phase 2a study of PTX-100 necessitates that the Company limits its investment into its Cell Therapy Platforms, these programs may be reactivated in the future.

### **Strategic Partnerships and Commercial Engagement**

Prescient has actively engaged with leading institutions and industry partners, including Yale, UPenn, Oxford, Moffitt, and Peter MacCallum Cancer Centre. These collaborations are instrumental in advancing our pipeline and validating our technologies. Our team has participated in multiple investor briefings and scientific forums, reinforcing our reputation as a forward-thinking innovator in oncology.

### **Financial Strength and Shareholder Support**

Prescient ended the financial year with a strong cash balance, and, subsequent to the end of the financial year in July 2025, we completed a \$6.8 million Share Purchase Plan and a \$3 million placement to support the Phase 2a development of PTX-100. I believe that the strong interest in both the SPP and the placement reflects strong shareholder support for the path plotted by the Company as well as the excitement for the future.

### **Transitions and Building for Growth**

During the year to 30 June 2025, the Board oversaw significant leadership transitions that position the Company for its next growth phase. On behalf of the Board, I acknowledge the sustained efforts of our outgoing CEO, Steven Yatomi-Clarke and our outgoing Chair, Steve Engle, and thank them both for their commitment to the Company. These departures created significant opportunities for Prescient as we build for the future, and we were delighted to welcome James McDonnell as CEO in January. James has had a long and successful career in biotech and pharma, and his clinical and commercialisation networks will be increasingly valuable as we progress PTX-100 through its phase 2a study. The Board also moved to build a strong executive team around the CEO, with the appointments of a new Chief Operating Officer, Dr Rebecca Tunstall and Chief Medical Officer, Dr Marissa Lim to help lead the established Prescient team. The Board was also delighted to welcome

Melanie Farris as a Non-Executive Director during the year. Melanie has substantial experience in the Australian biotechnology sector and her experience and perspective have enhanced the skill set of the Board.

### **Acknowledgments**

As we enter FY2026, Prescient is poised for an exciting year ahead. With a robust pipeline, a strong balance sheet, meaningful engagement with regulators and an expert team of seasoned drug development executives Prescient has never been in stronger position. We remain committed to our governance responsibilities while supporting management's execution of a strategy that creates long term shareholder value.

On behalf of the Board, I extend my sincere thanks to our patients, clinicians, and research collaborators, and to our loyal shareholders, thank you for your continued support and belief in our mission. The team looks forward to sharing the next phase of our journey with you.

Sincerely,

A handwritten signature in black ink, appearing to read "J Campbell", written in a cursive style.

Dr James Campbell  
Chair

20 August 2025

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Consolidated entity' or 'Prescient') consisting of Prescient Therapeutics Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2025.

### **Directors**

The following persons were directors of Prescient Therapeutics Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Dr James Campbell, Chair (Appointed on 30 March 2025)  
Dr Allen Ebens, Non-Executive Director  
Dr Ellen Feigal, Non-Executive Director  
Dr Gavin Shepherd, Non-Executive Director (Appointed on 4 July 2024)  
Ms Melanie Farris, Non-Executive Director (Appointed on 10 April 2025)  
Mr Steven Engle, Non-Executive Chair (Retired on 30 March 2025)  
Mr Steven Yatomi-Clarke, Managing Director and CEO (Resigned on 19 January 2025)

### **Principal activities**

During the financial year the principal activities of the Consolidated entity consisted of:

- preparation for and conduct of research and development of the Company's proprietary technologies and products including PTX-100;
- business development associated with the promotion of Prescient's proprietary technologies and products; and
- business development associated with developing collaborative, partnership relationships and corporate transactions.

### **Dividends**

There were no dividends paid, recommended or declared during the current or previous financial year.

### **Review of operations**

The loss for the Consolidated entity after providing for income tax amounted to \$7,322,531 (30 June 2024: \$8,238,050).

It was a year of significant progress for Prescient as the FDA accepted the Company's filing of an IND for the Phase 2a trial of PTX-100, allowing the trial to commence in the US while also giving PTX-100 Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. This marked another milestone for PTX-100 on the pathway to treating patients with refractory/relapsed Cutaneous T Cell Lymphoma (CTCL).

### **PTX-100**

#### *Phase 1b clinical trial*

During the reporting period, Prescient formally closed out the Phase 1b trial and migrated one ongoing patient who is still receiving clinical benefit onto compassionate use of PTX-100 to continue to manage their disease. On 21 March 2025, Prescient announced that additional data from its Phase 1b study of PTX-100 in T-cell lymphomas was presented at the 16th Annual T-Cell Lymphoma Forum in La Jolla, California, as a poster presentation that included pharmacokinetic characteristics, and some early biomarker assessments plus drug interaction studies. At the same conference, Principal Investigator Professor H. Miles Prince, AM gave a presentation that featured information pertaining to PTX-100.

As previously communicated, the interim results from the Phase 1b study showed a 45% overall response rate amongst all evaluable TCL patients, with 6 out of 7 CTCL patients receiving clinical benefit. The pharmacokinetic and drug interaction studies show no accumulation of the drug, and minimal drug interactions, supporting the safety profile for long term use of PTX-100. This encouraging result from the Phase 1b trial demonstrate the potential of PTX-100 as a treatment option for patient with r/r CTCL, allowing Prescient to move forward with the Phase 2 clinical trial in this indication which remains an area of significant unmet medical need.

#### *Phase 2 trial*

Prescient maintained momentum in preparing for the commencement of the Phase 2a clinical trial, with a particular focus on reviewing and refining the trial design. The Company actively sought and incorporated feedback from Key Opinion Leaders (KOL's) in T-Cell Lymphoma (TCL) and from the regulatory agency into the trial design. Feedback from manufacturing, and commercial experts were also sought to ensure the clinical trial is run with efficiency and to minimise cost.

On 23 December 2024, Prescient announced that the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug (IND) application for the Phase 2 clinical trial of PTX-100, the Company's first-in-class Ras pathway inhibitor, for relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL). The IND clearance paved the way for commencement of the Phase 2 study in the USA.

On 26 March 2025, Prescient announced the completion of the first Site Initiation Visit (SIV) for its Phase 2a clinical study of



PTX-100, and first operational site under Principal Investigator Professor Miles Prince, AM at the Epworth Freemasons Haematology Clinical Trial Unit. This achievement represented a significant milestone in the development of PTX-100 as a treatment for Cutaneous T-Cell Lymphoma.

On 27 May 2025, Prescient announced that the first patient had been dosed in its Phase 2a clinical study of PTX-100 at the Linear Clinical Research site in Perth under the care of Dr. Dejan Radeski.

In parallel to the progress with the Phase 2a clinical trial, on 16 April 2025, Prescient announced that PTX-100 received U.S. FDA Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL. This designation provides several benefits including increased access to the FDA, the possibility of rolling submissions of New Drug Applications, and a pathway to Accelerated Approvals, representing a critical milestone toward Prescient's goal of advancing PTX-100 into a registration-enabling trial. The Fast Track designation indicated that the FDA recognised PTX-100 trial data already shows promise as a potential treatment option for an unmet medical need in this patient population.

Substantial Chemistry, Manufacturing, and Control (CMC) activities are ongoing to support PTX-100's development plans. CMC capabilities have been substantially bolstered to conduct all necessary activities. It is important to note that CMC requirements for programs preparing for registration studies are considerably more detailed and stringent than for earlier stage clinical studies.

### **PTX-200**

The PTX-200 clinical trial in Acute Myeloid Leukaemia formally closed out and the database locked for data analysis as of 3 September 2024. At the date of this report, the Company is preparing the written clinical study report for this trial.

### **CellPryme**

CellPryme data that was previously presented by Dr Christina Scheffler PhD from the Peter MacCallum Cancer Centre at the ISCT-ANZ Regional Scientific Meeting in Perth in August 2023, was written as a publication for submission to a high impact journal. Prescient and collaborators at the Peter MacCallum Cancer Centre (PMCC) demonstrated an impact on the tumour microenvironment when a tumour is pre-treated with Cell Pryme A. This was elucidated in the publication submission. The Company anticipated the outcomes of these studies would provide valuable insights into how CellPryme could overcome TME resistance and enhance the efficacy of other therapies in combination with Cell Pryme A.

### **OmniCAR**

As Prescient's proprietary next-generation CAR-cell platform, OmniCAR was designed to revolutionise cellular immunotherapy by providing modular, controllable, and reprogrammable CAR-cell therapies.

Previously, Prescient observed that OmniCAR T-cells unarmed with antigen binders were demonstrating unexpected activity. Such an observation was counter to the modular, controllable thesis of OmniCAR and needed to be resolved before undertaking further development. As planned, Prescient devoted time to troubleshooting and engineering a solution, a complex effort requiring multidisciplinary inputs including bioinformatics, protein engineering, immunology and cell biology, achieved through collaboration between Prescient, the Peter McCallum Cancer Centre and the CSIRO.

On 23 January 2025 Prescient reported that this highly technical effort was successful, with the design of several OmniCAR variants that have overcome the problems observed with the previous OmniCAR construct in preliminary in vitro and in vivo testing.

Specifically, T cells expressing the new OmniCAR variants demonstrated greatly improved safety when unarmed in both in vitro and in vivo studies. When armed with binders, these new OmniCAR variants demonstrated highly effective tumour-killing activity in mice with Her2 positive tumours, with duration of efficacy exceeding that of the previous version of OmniCAR.

Prescient maintains the view that modularity can play a transformative role in cell therapies, and that this development will position OmniCAR favourably for when the cell therapy sector regains buoyancy.

### **Building awareness of the Company's programs**

Prescient attended and presented its PTX-100 data at the TCL Forum in San Diego further defining the PK characteristics and PD biomarkers. PTX-100 was mentioned by investigators in a number of presentations at the meeting. This action will assist in building awareness within the TCL treatment community as well as building a base of potential partners and collaborators.

Prescient continues to engage with potential partners in the Cell therapy sector. In particular with reference to Cell Pryme M

and distribution partnership. OmniCAR partner engagement remained in a holding pattern awaiting validation of the new constructs.

#### *Financial performance*

In the year ended 30 June 2025, the Consolidated entity has recognised an estimated research and development ("R&D") tax incentive rebate for the year of \$4,356,397 (2024: \$3,712,364) for eligible R&D expenses of \$6,716,568 (2024: \$6,973,046).

Corporate expenses decreased to \$931,588 (2024: \$998,430) and were primarily attributable to a decrease in professional fees paid.

Employment related expenses increased to \$3,719,499 (2024: \$2,434,455) and were primarily attributable to an increase in consulting fee and share-based payments during the year ended 30 June 2025.

#### *Financial position*

Net assets of \$11,387,172 (2024: \$18,067,288), primarily being cash and cash equivalents decreased during the year reflecting expenditure for R&D costs, corporate expenses and employment costs during the year.

#### **Key risks and uncertainties**

The Consolidated entity is subject to risks specific to its business activities, as well as general risks.

#### *Successful commercialisation of assets*

The inherent nature of research and development is uncertain. There are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. This would have a material impact on the Company.

Prescient mitigates risk where reasonably possible through diversification of its product pipeline, undertaking rigorous scientific review during the development process, and working with reputable and capable partners and service providers.

#### *Future funding risk*

At 30 June 2025, the Company had a cash balance of \$6,906,804 and net assets of \$11,387,172 and is continuing operations on a going concern basis. However, there is risk that the Company may require substantial additional financing in the future to sufficiently fund its operations, research and development.

In addition, in many territories, products such as those being developed by the Company, must follow a formal reimbursement process in order to be commercially successful. The availability and timing of reimbursement may have an impact upon the uptake and future profitability of products in some jurisdictions.

The Directors regularly review the spending pattern of the Company and the Company's ability and likelihood of raising additional funds to ensure the Company's ability to generate sufficient cash inflows to continue operations and settle its creditors and other liabilities as and when they fall due. In addition, at the date of this Report, Prescient remains eligible for certain government grants and the refundable R&D tax incentive.

#### *Regulatory and licensing risk*

If Prescient does not obtain necessary regulatory approvals it may be unable to commercialise its products. Even if it receives regulatory approval for any product candidates, profitability will depend on its ability to generate revenues from the sale of its products or the licensing of its technology.

The Company monitors legislative and regulatory developments and engages proactively with key stakeholders to manage this risk.

#### *Competition and dependence on commercial partners and future licence arrangements*

There is no guarantee that a product will be commercially viable, even if approved for sale. Products may be subject to detrimental competition from competing therapies, or changes in therapeutic practices. There is no guarantee that the Company will be able to find suitable partners that it can negotiate attractive commercial terms for licence or sale agreements for new or existing products. The success of the Company's partnering arrangements may depend on resources devoted to them by itself or its industry partners. Collaborative agreements may also be terminated. Non-performance, suspension or termination of relevant agreements is likely to have a material and adverse impact on the Company's operations and financial performance.

#### *Reliance on key personnel*

Prescient's success depends to a large extent upon its key management personnel, as well as other management and technical personnel including those employed on a contractual basis. The loss of the services of such personnel or the reduced

ability to recruit additional personnel could have an adverse effect on performance.

The Company maintains a mixture of in-house personnel and external consultants to allow access to multiple sources of human resource. The Remuneration and Nomination Committee of the Board oversees attraction, retention, reward and recognitions strategies of the Company in line with culture and performance objectives.

*Inability to protect intellectual property*

The Company's ability to leverage its innovation and expertise is dependent on its ability to protect its intellectual property and any improvements to it. A failure or inability to protect the Company's intellectual property rights could have an adverse impact on operating and financial performance.

Prescient proactively monitors applications and renewals of patents and licences, and has information control and security policies and procedures in place.

*IT system failure and cyber security risk*

Any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet and data network failures, and natural disasters. The potential financial impacts of cyber security breaches may include:

- Business disruption costs
- Intellectual property or other valuable data being stolen or compromised
- Breaches of confidentiality with external parties that may compromise material commercial agreements
- Costs of remedying breaches and recovering data
- Costs to bolster cyber protection
- Litigation and legal costs
- Reputational damage

The Company aims to continuously monitor and enhance information security capabilities to keep pace with the evolving nature and sophistication of cyber threats in its efforts to continuously enhance our ability to prevent, detect and respond to cyber-attacks.

*Physical and transition climate-related risks*

Acute climate-related risks may manifest when physical risks, such as flooding or storms disrupt the Company's operations, rented corporate service arrangements and/ or material supply chain partners. Chronic climate-related risks can come from long-term changes in precipitation, extreme variability in weather patterns, rising mean temperatures and/or rising sea levels. There is uncertainty over the future environmental policy and fiscal landscape in many countries where we may operate. We anticipate increased regulation and other developments related to carbon pricing and broader environmental taxation over the medium to long-term. We may face increased pricing of greenhouse gas (GHG) emissions, enhanced emissions-reporting obligations, mandates on and regulation of existing products and services, which may in turn increase our exposure to litigation.

The Company will seek to mitigate material business impact arising from short-term events primarily through thoughtful design and sustainability of supply chains. We will assess and determine suppliers with high criticality and exposure to significant future climate hazards, and will aim to work with them to ensure that they build climate-related resilience into their business continuity plans. We aim to maintain awareness of current and emerging policy across our areas of operation. We will incorporate awareness of emerging issues into our business sustainability thinking and decision-making. We aim to understand our GHG footprint and set targets to reduce or offset our emissions where applicable.

**Significant changes in the state of affairs**

Mr Steven Yatomi-Clarke resigned as the Chief Executive Officer and Managing Director effective 19 January 2025, and Mr James McDonnell commenced as Chief Executive Officer effective 20 January 2025.

The executive team was further strengthened with the announcement of a new Chief Medical Officer, Dr Marissa Lim, on 24 March 2025

As part of the ongoing Board renewal process, Dr Gavin Shepherd was appointed as Non-Executive Director on 4 July 2024. On 30 March 2025, Mr Steven Engle retired as Chair and stood down from the Board of Directors. Non-Executive Director, Dr James Campbell, was appointed Chair on 30 March 2025. The Board was further enhanced with the appointment of Ms Melanie Farris as Non-Executive Director on 10 April 2025.

There were no other significant changes in the state of affairs of the Consolidated entity during the financial year.

#### **Matters subsequent to the end of the financial year**

On 31 July 2025, the Company announced that 74,462,500 ordinary shares to be sophisticated and professional investors at \$0.04 per share under a Placement to raise \$3,000,000 (before costs).

On 4 August 2025, the Company issued 171,732,250 ordinary shares at \$0.04 (4 cents) per share and raised \$6.8 million (before costs) upon completion of Share Purchase Plan ("SPP") on 29 July 2025.

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Consolidated entity's operations, the results of those operations, or the Consolidated entity's state of affairs in future financial years.

#### **Likely developments and expected results of operations**

The Company continues to develop its targeted therapies and cell therapies, to treat a range of haematological and solid cancers. The expected results of operations for the consolidated entity will depend on the result of these studies.

#### **Environmental regulation**

Prescient is required to carry out its activities in accordance with applicable environment and human safety regulations in each of the jurisdictions in which it undertakes its operations. The Company is not aware of any matter that requires disclosure with respect to any significant regulations in respect of its operating activities, and there have been no issues of non-compliance during the year. The Company retains the right, under the respective contracts, to audit the performance of its contractors.

#### **Information on Directors**

Name:	Dr James Campbell
Title:	Appointed Non-Executive Director on 28 November 2014 Appointed Chair of the Board on 30 March 2025
Qualifications:	Ph.D, MBA, GAICD
Experience and expertise:	Dr James Campbell was appointed as a Director of the Company in November 2014. Dr Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. Dr Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS), where, as a member of the executive team he helped transform a research-based company with a market capitalization of \$10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for \$230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with successful capital raising and partnering negotiations. Dr Campbell chairs the Board of Australia's peak biotechnology body, AusBiotech.
Other current directorships:	Non-Executive Director of Patrys Limited (ASX:PAB)
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Audit and Risk Committee
Interests in shares:	1,368,365 Fully Paid Ordinary Shares
Interests in options:	None

**Name:** Dr Allen Ebens  
**Title:** Appointed Non-Executive Director on 1 June 2020  
**Qualifications:** BSc., PhD.  
**Experience and expertise:** Dr Allen Ebens was appointed as a Director of the Company in June 2020. During that time Dr Ebens as head of Research at Vera Therapeutics, a San Francisco, California based, clinical stage biotechnology company. Dr Ebens is a highly accomplished drug developer, having overseen the advancement of a dozen successful drug development projects from concept to clinical development including polatuzumab and mosunetuzumab which are FDA approved and marketed for use in B-cell malignancies. Dr Ebens was an early recruit to Juno Therapeutics, a founding CAR-T company, and a leader in the successful and rapid clinical advancement of CAR-T cancer therapies. At Juno, Dr Ebens was instrumental in establishing the scientific capabilities of the company in the emerging field of CAR-T. Previously, Dr Ebens held senior executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across multiple therapeutic platforms including targeted small-molecule therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He has also held roles in biotech companies including Bioseek and NGM Biopharmaceuticals.

**Other current directorships:** None  
**Former directorships (last 3 years):** None  
**Special responsibilities:** Member of the Audit and Risk Committee  
**Interests in shares:** None  
**Interests in options:** None

**Name:** Dr Ellen Feigal  
**Title:** Appointed Non-Executive Director on 15 May 2023  
**Qualifications:** MD, MS  
**Experience and expertise:** Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law.

Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a world-leading research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.

Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.

Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncology fellowship at the University of California, San Francisco.

**Other current directorships:** Xencor Inc (NASDAQ: XNCR), NextCure Inc (NASDAQ: NXTC)  
**Former directorships (last 3 years):** None  
**Special responsibilities:** Member of Remuneration and Nomination Committee  
**Interests in shares:** None  
**Interests in options:** 1,415,000 at \$0.1309, expiring 15 May 2027

Name:	Dr Gavin Shepherd
Title:	Appointed Non-Executive Director on 4 July 2024
Qualifications:	BMBS, GDOH, FAFOEM(RACP), GAICD
Experience and expertise:	Dr Shepherd is an accomplished medical professional with 25 years of experience in medicine and a proven track record in driving success in various specialist consulting businesses. After completing his medical qualification at Flinders University, he completed specialist training as a consultant Occupational and Environmental Physician with a fellowship from the Royal Australasian College of Physicians. He completed his GAICD qualification in 2011 and is a non-executive director of Lateral Pharma Pty Ltd.  Dr Shepherd combines his medical expertise with strong business acumen, demonstrated by his business success as well as through his investment in disruptive healthcare technologies. He actively contributes to the healthcare industry through his involvement with the Medical Device Partnering Program at Flinders University and his lecturing for the Royal Australian College of General Practitioners registrar training program in South Australia.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Member of the Remuneration and Nomination Committee and Audit and Risk Committee
Interests in shares:	17,500,000 Fully Paid Ordinary Shares
Interests in options:	1,415,000 at \$0.0621, expiring 11 December 2028
Name:	Ms Melanie Farris
Title:	Appointed Non-Executive Director on 10 April 2025
Qualifications:	FGIA, FCG, GAICD, BCom and Grad Dip ACG
Experience and expertise:	Ms Farris is an experienced non-executive director, governance, risk and communications professional in the listed, public and not-for-profit sectors, possessing a strong track record in the planning, delivery and oversight of strategic corporate, funding, governance and risk projects across industries including life sciences, investment, agriculture, not-for-profit and music industry marketing.  With extensive senior executive tenure including as chief governance and risk officer, chief financial officer, chief operating officer, group company secretary, senior risk and sustainability advisor, prior roles include with Telix Pharmaceuticals Limited (ASX: TLX), Factor Therapeutics Limited (ASX: FTT), Invion Limited (ASX: IVX), Menzies Research Centre, HRH The Prince of Wales's Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince's Foundation.  Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Chair of Audit and Risk Committee, Chair of Remuneration and Nomination Committee
Interests in shares:	625,000 Fully Paid Ordinary Shares
Interests in options:	None



Name: Mr Steven Engle  
 Title: Non-Executive Chair until 30 March 2025  
 Qualifications: M.S.E.E. and B.S.E.E.  
 Experience and expertise: Steven Engle was appointed as a Director of the Company in June 2014. He is a resident of the US and has over two decades of executive leadership experience with public and private biotechnology companies developing breakthrough products in metabolic, autoimmune, oncologic and infectious disease areas. Most recently, Steve was the CEO of Gradalis, a biotechnology company focused on the development of personalized cellular immunotherapies to treat cancer, and which is preparing a clinical study for product registration in patients with ovarian cancer.

Other current directorships: Author-It Software Company.  
 Former directorships (last 3 years): AROA Biosurgery (ASX:ARX), Gradalis, CohBar (NASDAQ:CWBR)

Name: Mr Steven Yatomi-Clarke  
 Title: Managing Director and CEO until 19 January 2025  
 Qualifications: BSc(Hons), BCom  
 Experience and expertise: Mr Yatomi-Clarke was appointed as CEO and Managing Director of Prescient Therapeutics in February 2016, having previously been a Non-executive Director of the Company. Mr Yatomi-Clarke holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has also been a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy.

Other current directorships: None  
 Former directorships (last 3 years): None  
 Special responsibilities: None

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

### **Company Secretary**

*Melanie Leydin – BBus (Acc. Corp Law) FCA FGIA*

Melanie holds a Bachelor of Business majoring in Accounting and Corporate Law. Melanie is a Fellow of the Institute of Chartered Accountants and Fellow of the Governance Institute of Australia. Melanie graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and from February 2000 to October 2021 was the principal of Leydin Freyer which was acquired by Vistra in November 2021. Melanie is now the Executive Vice President of Global Solutions, South East Asia at Vistra. Vistra is a prominent provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors.

Melanie has over 30 years' experience in the accounting profession and over 20 years' experience holding Board positions including company secretary and CFO of ASX listed entities. Melanie has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies, initial public offerings, secondary raisings and shareholder relations.

## Meetings of Directors

The number of meetings of the Company's Board of Directors ('the Board') and of each Committee of the Board held during the year ended 30 June 2025, and the number of meetings attended by each Director were:

	Full Board		Remuneration and Nomination Committee		Audit and Risk Committee	
	Eligible to attend	Attended	Eligible to attend	Attended	Eligible to attend	Attended
Dr James Campbell	9	9	1	1	2	2
Dr Allen Ebens	8	9	-	-	1	1
Dr Ellen Feigal	9	9	1	1	-	-
Dr Gavin Shepherd	9	9	1	1	1	1
Ms Melanie Farris	2	2	-	-	-	-
Mr Steven Engle	7	7	1	1	-	-
Mr Steven Yatomi-Clarke	5	5	-	-	-	-

## Remuneration report (audited)

This remuneration report for the year ended 30 June 2025 outlines the remuneration arrangements of the consolidated entity in accordance with the requirements of the Corporations Act 2001 and its Regulations. This information has been audited as required by section 308(3C) of the Act.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

### **Principles used to determine the nature and amount of remuneration**

The objective of the Company's executive remuneration framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- competitiveness and reasonableness
- acceptability to shareholders
- performance linkage / alignment of executive compensation
- transparency

The Remuneration and Nomination Committee is responsible for determining and reviewing remuneration arrangements for its directors and executives. The remuneration philosophy is set to attract, motivate and retain high performance and high quality personnel.

The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it should seek to enhance shareholders' interests by:

- focussing on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value
- attracting and retaining high calibre executives

Additionally, the reward framework should seek to enhance executives' interests by:

- rewarding capability and experience
- reflecting competitive reward for contribution to growth in shareholder wealth
- providing a clear structure for earning rewards

In accordance with best practice corporate governance, the structure of non-executive Director and executive Director remuneration is separate.



#### *Non-executive Directors remuneration*

Fees and payments to non-executive directors reflect the demands and responsibilities of their role. Non-executive directors' fees and payments are reviewed annually by the Remuneration and Nomination Committee. The Remuneration and Nomination Committee may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The Chair's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market.

ASX Listing Rules require the aggregate non-executive directors remuneration be determined periodically by a General Meeting. The most recent determination was at the Annual General Meeting held 9 November 2004, where the Shareholders approved an aggregate remuneration pool of \$400,000.

#### *Executive remuneration*

The Consolidated entity aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.

The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits
- short-term performance incentives
- share-based payments
- other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the Remuneration and Nomination Committee based on individual and business unit performance, the overall performance of the consolidated entity and comparable market remunerations.

Executives may receive their fixed remuneration in the form of cash or other fringe benefits (for example motor vehicle benefits) where it does not create any additional costs to the Consolidated entity and provides additional value to the executive.

#### *Short-term incentives*

The short-term incentives ('STI') program is designed to align the targets of the business units with the performance hurdles of executives. STI payments are granted to executives based on specific annual targets and key performance indicators ('KPI's') being achieved. KPI's include profit contribution, customer satisfaction, leadership contribution and product management.

#### *Long-term incentives*

The long-term incentives ('LTI') include share-based payments under the Executive Option Plan (EOP) and have been selected to align Company performance and reflect individual employee contribution to the Company. Directors and other key management personnel receive compensation under these plans.

Options are awarded to executives over a period of two to four years based on long-term incentive measures using time-based milestones.

Shares are issued to executives under the EOP based on the achievement of performance hurdles. Performance hurdles are decided on an individual basis as approved by the Board and are based on financial and non-financial targets.

#### *Performance and link to remuneration*

The remuneration of the Non-Executive Directors is not directly linked to the performance of the Company. Via the cash bonus and incentive payments, the remuneration of the CEO and other senior executives is linked to the performance of the Company. The achievement of any bonus or incentive is based upon the annual corporate goals set by the Board at the beginning of each financial year.

During the year ended 30 June 2025 the Company did not engage an external remuneration consultant.

### Details of remuneration

The Remuneration Report details the remuneration arrangements for key management personnel ('KMP') who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director, whether executive or otherwise.

For the year ended 30 June 2025, KMP of the Company comprised non-executive directors, executive directors and other key management personnel as follows:

Dr James Campbell, Chair (Appointed 30 March 2025)  
Dr Allen Ebens, Non-Executive Director  
Dr Ellen Feigal, Non-Executive Director  
Dr Gavin Shepherd, Non-Executive Director (Appointed on 4 July 2024)  
Ms Melanie Farris, Non-Executive Director (Appointed on 10 April 2025)  
Mr Steven Engle, Non-Executive Chair (Retired on 30 March 2025)  
Mr Steven Yatomi-Clarke, Managing Director and CEO (Resigned on 19 January 2025)  
Mr James McDonnell, Chief Executive Officer (Appointed on 20 January 2025)

### Amounts of remuneration

Details of the remuneration of key management personnel of the Consolidated entity are set out in the following tables.

	Short-term benefits	Short-term benefits	Post- employment benefits	Long-term benefits	Share- based payments Equity-	Non- Monetary	
	Cash salary and fees	Bonus	Super- annuation	Long service leave	settled options	Benefits	Total
2025	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
Dr James Campbell <sup>(1)</sup>	68,750	-	-	-	-	-	68,750
Dr Allen Ebens	60,000	-	-	-	-	-	60,000
Dr. Ellen Feigal	60,000	-	-	-	14,674	-	74,674
Dr Gavin Shepherd <sup>(2)</sup>	59,355	-	-	-	16,771	-	76,126
Ms Melanie Farris <sup>(3)</sup>	14,168	-	-	-	-	-	14,168
Mr Steven Engle <sup>(4)</sup>	83,333	-	-	-	-	-	83,333
<i>Executive Directors:</i>							
Mr Steven Yatomi-Clarke <sup>(5)</sup>	346,698	-	25,933	58,914	-	58,133	489,678
<i>Other Key Management Personnel:</i>							
Mr James McDonnell <sup>(6)</sup>	171,725	-	18,069	2,969	167,672	-	360,435
	864,029	-	44,002	61,883	199,117	58,133	1,227,164

(1) Appointed Chair on 30 March 2025. Dr Campbell received his remuneration through Barrabool Biotechnology Pty Ltd (an entity associated with him).

(2) Appointed on 4 July 2024.

(3) Appointed on 10 April 2025.

(4) Retired as Chair and non-executive director effective 30 March 2025. Subsequent to him leaving the Board, the Company entered into a consulting and advisory services agreement with Mr Engle which expires on 30 March 2026 and is capped at \$60,000 for the term of the agreement.

(5) Resigned on 19 January 2025. Non-monetary benefits including fringe benefit tax arising from the provision of Loan Funded Shares provided to Mr Steven Yatomi-Clarke will be paid for by the Company.

(6) Appointed on 20 January 2025.

	Short-term benefits	Short-term benefits	Post- employment benefits	Long-term benefits	Share- based payments Equity-	Non- Monetary	
	Cash salary and fees	Bonus	Super- annuation	Long service leave	settled options	Benefits**	Total
2024	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
Mr Steven Engle	95,000	-	-	-	2,956	-	97,956
Dr James Campbell *	60,000	-	-	-	1,407	-	61,407
Dr Allen Ebens	60,000	-	-	-	1,407	-	61,407
Dr Ellen Feigal	60,000	-	-	-	32,617	-	92,617
<i>Executive Directors:</i>							
Mr Steven Yatomi-Clarke **	414,139	105,000	42,844	10,925	18,156	65,943	657,007
	689,139	105,000	42,844	10,925	56,543	65,943	970,394

\* Dr Campbell received his remuneration through Barrabool Biotechnology Pty Ltd (an entity associated with him).

\*\* Non-monetary benefits including fringe benefit tax arising from the provision of Loan Funded Shares provided to Mr Steven Yatomi-Clarke will be paid for by the Company.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration		At risk - LTI		At risk - STI	
	2025	2024	2025	2024	2025	2024
<i>Non-Executive Directors:</i>						
Dr James Campbell	100%	100%	-	-	-	-
Dr Allen Ebens	100%	100%	-	-	-	-
Dr Ellen Feigal	100%	100%	-	-	-	-
Dr Gavin Shepherd	100%	-	-	-	-	-
Ms Melanie Farris	100%	-	-	-	-	-
Mr Steven Engle	100%	100%	-	-	-	-
<i>Executive Directors:</i>						
Mr Steven Yatomi-Clarke	71%	81%	29%	3%	-	16%
<i>Other Key Management Personnel:</i>						
Mr James McDonnell	53%	-	47%	-	-	-

### **Service agreements**

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	James McDonnell
Title:	CEO
Agreement commenced:	20 January 2025
Term of agreement:	No fixed term, commencing on 20 January 2025 for an ongoing term subject to termination by the Company with six months' notice or by Mr McDonnell with six months' notice.
Details:	Mr McDonnell is entitled to an annual salary of \$350,000 plus superannuation of \$40,250, subject to annual review. In addition, Mr McDonnell a performance- based bonus over and above the annual salary. This bonus is split between short-term incentives and long-term incentives and is capped at one third of the annual salary as at the date of payment of the bonus. The STI bonus amount is payable within 30 days upon achievement of relevant milestones. Three months before the commencement of each subsequent year, the Board and the Employee will agree the milestones applicable to the achievement of the Bonus amount for those years. Mr McDonnell is eligible to receive an annual bonus of up to 30% of base salary based on the achievement of annual corporate goals set by the Board. The CEO is eligible to participate in the company's long term incentive plan.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

### **Share-based compensation**

#### **Share loan plan**

On 30 November 2016, shareholders approved the Company's proposal to issue up to 8,000,000 Loan Funded Shares (LFS) with an expiry date of 30 November 2021 to the Company's former Managing Director, Mr Steven Yatomi-Clarke, by way of interest-free loan with no fixed loan repayment date and with recourse to the funding provided for the ordinary shares limited to the outstanding amount drawn down. Should there be a shortfall in the ability of the borrower to settle in full the outstanding amount, the Company may not bring legal proceedings to recover the amount. If the employee sells the shares, the loan amount outstanding is payable on the date of receipt of the funds. A total of 6,000,000 shares were issued under LFS in prior years and the remaining 2,000,000 shares expired on 30 November 2021. The issued ordinary shares have full voting rights and the right to receive dividends, noting that any dividends paid on shares excluding franking credits will first be applied to pay outstanding amounts drawn down.

During the year ended 30 June 2025, 6,000,000 shares under LFS were disposed by Mr Steven Yatomi-Clarke for the consideration of \$293,404. The consideration and respective fair value of the LFS of \$617,404 were accounted for as share capital in equity in recognition of the previously issued LFS shares. Following the resignation of Mr Steven Yatomi-Clarke, the loan funded share arrangement expired. No further share-based payment expense was incurred during the period in relation to the above transaction.

There were no further shares issued and nil loan funded share balance at 30 June 2025 (30 June 2024: 6,000,000 and \$928,000 respectively).

*Options*

Grant date	Vesting date and exercisable date	Expiry date	Number of options granted	Exercise price	Fair value per option at grant date
11 May 2023	11 May 2023	9 May 2027	353,750	\$0.1309	\$0.06
11 May 2023	11 May 2024	9 May 2027	353,750	\$0.1309	\$0.06
11 May 2023	11 May 2025	9 May 2027	353,750	\$0.1309	\$0.06
11 May 2023	11 May 2026	9 May 2027	353,750	\$0.1309	\$0.06
11 December 2024	11 December 2024	11 December 2028	353,750	\$0.0621	\$0.03
11 December 2024	11 December 2025	11 December 2028	353,750	\$0.0621	\$0.03
11 December 2024	11 December 2026	11 December 2028	353,750	\$0.0621	\$0.03
11 December 2024	11 December 2027	11 December 2028	353,750	\$0.0621	\$0.03
20 January 2025	20 January 2026	20 January 2030	6,000,000	\$0.0812	\$0.03
20 January 2025	20 January 2027	20 January 2030	6,000,000	\$0.0812	\$0.03
20 January 2025	20 January 2028	20 January 2030	6,000,000	\$0.0812	\$0.03
20 January 2025	19 January 2029	20 January 2030	6,000,000	\$0.0812	\$0.03
			<u>26,830,000</u>		

The options over ordinary shares granted to or vested by Directors and other key management personnel as part of compensation during the year ended 30 June 2025 are as follows:

Name	Number of options granted during the year 30 June 2025	Number of options vested during the year 30 June 2025
Mr James McDonnell	24,000,000	-
Dr Ellen Feigal	-	353,750
Dr Gavin Shepherd	1,415,000	353,750
	<u>25,415,000</u>	<u>707,500</u>

**Additional information**

The earnings of the Consolidated entity for the five years to 30 June 2025 are summarised below:

	2025 \$	2024 \$	2023 \$	2022 \$	2021 \$
Revenue	225,611	687,577	459,098	44,177	66,285
Net profit/(loss) before tax	(7,322,531)	(8,238,050)	(7,004,501)	(5,117,176)	(4,148,819)
Net profit/(loss) after tax	(7,322,531)	(8,238,050)	(7,004,501)	(5,117,176)	(4,148,819)
	2025	2024	2023	2022	2021
Share price at year end (cents)	4.40	3.80	8.10	15.50	24.50

### Additional disclosures relating to key management personnel

#### Shareholding

The number of shares in the Company held during the financial year by each Director and other members of key management personnel of the Consolidated entity, including their personally related parties, is set out below:

	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
<i>Ordinary shares</i>					
Dr James Campbell	396,365	-	222,000	-	618,365
Ms Melanie Farris <sup>(1)</sup>	-	-	250,000	-	250,000
Dr Gavin Shepherd <sup>(2)</sup>	-	-	850,000	16,150,000	17,000,000
Mr Steven Yatomi-Clarke <sup>(3)</sup>	11,195,017	-	-	(11,195,017)	-
Dr Steven Engle <sup>(4)</sup>	219,939	-	-	(219,939)	-
	<u>11,811,321</u>	<u>-</u>	<u>1,322,000</u>	<u>4,735,044</u>	<u>17,868,365</u>

(1) Appointed 10 April 2025

(2) Appointed 4 July 2024. 16,150,000 shares were held at commencement of tenure.

(3) Resigned 19 January 2025

(4) Retired 30 March 2025

#### Option holding

The number of options over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Consolidated entity, including their personally related parties, is set out below:

	Balance at the start of the year	Granted as part of remuneration	Exercised	Expired/ forfeited	Balance at the end of the year
<i>Exercised and expired / forfeited with payment of employee share loans and expiry of employee share loan.</i>					
Dr James Campbell	1,000,000	-	-	(1,000,000)	-
Dr Allen Ebens	1,000,000	-	-	(1,000,000)	-
Dr Ellen Feigal	1,415,000	-	-	-	1,415,000
Dr Gavin Shepherd	-	1,415,000	-	-	1,415,000
Mr James McDonnell *	-	24,000,000	-	-	24,000,000
Mr Steven Yatomi-Clarke **	12,900,000	-	-	(12,900,000)	-
Mr Steven Engle ***	2,100,000	-	-	(2,100,000)	-
	<u>18,415,000</u>	<u>25,415,000</u>	<u>-</u>	<u>(17,000,000)</u>	<u>26,830,000</u>

\* Appointed 20 January 2025

\*\* Resigned 19 January 2025

\*\*\* Retired 30 March 2025

#### Loans to key management personnel and their related parties

Other than the Loan Funded Share arrangement with Mr Yatomi-Clarke as described above, there were no loans to Key Management Personnel at any time during the financial year (2024: Nil).

#### Other transactions with key management personnel and their related parties

During the year ended 30 June 2025 6,000,000 shares under LFS were disposed with the consideration of \$293,404 which was outstanding as at 30 June 2025.

There were no other transactions with Key Management Personnel other than those disclosed above.

**This concludes the remuneration report, which has been audited.**

### **Shares under option**

Unissued ordinary shares of Prescient Therapeutics Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
10 December 2020	8 December 2025	\$0.0968	3,000,000
31 May 2021	31 May 2026	\$0.3580	4,000,000
18 October 2021	17 October 2026	\$0.4120	200,000
21 October 2021	20 October 2026	\$0.4120	200,000
22 October 2021	21 October 2026	\$0.4120	200,000
29 October 2021	28 October 2026	\$0.4120	200,000
3 November 2021	2 November 2026	\$0.4120	200,000
11 May 2023	9 May 2027	\$0.1309	1,415,000
11 December 2024	11 December 2028	\$0.0621	1,415,000
20 January 2025	20 January 2030	\$0.0812	24,000,000
			<u>34,830,000</u>

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

### **Indemnity and insurance of officers**

During the financial year, Prescient Therapeutics Limited paid an insurance premium in respect of a contract insuring directors, secretaries and executive officers of the Company and its controlled entities against a liability incurred as director, secretary or executive officer to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

The Company has not otherwise, during or since the end of the financial year, except to the extent permitted by law, indemnified or agreed to indemnify an officer or auditor of the Company or any of its controlled entities against a liability incurred as such an officer or auditor.

### **Indemnity and insurance of auditor**

To the extent permitted by law, the Company has agreed to indemnify the auditors, William Buck, as part of the terms of its audit engagement agreement against claims by third parties arising from the audit (for an unspecified amount). No payments have been made to indemnify William Buck during or since the financial year.

### **Proceedings on behalf of the Company**

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

### **Non-audit services**

There were no non-audit services provided during the financial year by the auditor.

### **Officers of the Company who are former directors of William Buck**

There are no officers of the Company who are former directors of William Buck.

### **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

### **Auditor**

William Buck continues in office in accordance with section 327 of the Corporations Act 2001.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the Directors

A handwritten signature in black ink, appearing to be "J Campbell", written over a horizontal line.

---

Dr James Campbell  
Chair

20 August 2025




## Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

### To the directors of Prescient Therapeutics Limited

As lead auditor for the audit of Prescient Therapeutics Limited for the year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Prescient Therapeutics Limited and the entities it controlled during the year.



**William Buck Audit (Vic) Pty Ltd**  
ABN 59 116 151 136



**R. P. Burt**  
Director  
Melbourne, 20 August 2025

**Prescient Therapeutics Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the year ended 30 June 2025**



	<b>Note</b>	<b>Consolidated 2025 \$</b>	<b>2024 \$</b>
Interest revenue		225,611	687,577
Other income	5	4,356,397	3,712,364
<b>Expenses</b>			
Research and development costs		(6,716,568)	(6,973,046)
Employment costs		(3,370,488)	(2,222,719)
Corporate expenses		(931,588)	(998,430)
Administrative expenses		(524,500)	(492,851)
Impairment of intangible assets (write off)	11	-	(1,716,718)
Share based payments	27	(349,011)	(211,736)
Foreign exchange translation		(12,384)	(22,491)
<b>Loss before income tax expense</b>		<b>(7,322,531)</b>	<b>(8,238,050)</b>
Income tax expense		-	-
<b>Loss after income tax expense for the year attributable to the Owners of Prescient Therapeutics Limited</b>		<b>(7,322,531)</b>	<b>(8,238,050)</b>
Other comprehensive income for the year, net of tax		-	-
<b>Total comprehensive loss for the year attributable to the Owners of Prescient Therapeutics Limited</b>		<b><u>(7,322,531)</u></b>	<b><u>(8,238,050)</u></b>
		<b>Cents</b>	<b>Cents</b>
Basic losses per share	26	(0.91)	(1.02)
Diluted losses per share	26	(0.91)	(1.02)

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Prescient Therapeutics Limited**  
**Consolidated statement of financial position**  
**As at 30 June 2025**



	<b>Note</b>	<b>Consolidated 2025 \$</b>	<b>2024 \$</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	6	6,906,804	10,493,183
Trade and other receivables	7	264,295	206,632
Amount due under loan funded share arrangement	8	293,404	-
Other financial assets	9	20,000	4,020,000
Prepayments	10	1,063,150	308,397
R&D tax incentive receivable	5	4,356,397	3,712,364
Total current assets		<u>12,904,050</u>	<u>18,740,576</u>
<b>Non-current assets</b>			
Plant and equipment		7,395	2,099
Intangibles	11	<u>1,650,176</u>	<u>1,650,176</u>
Total non-current assets		<u>1,657,571</u>	<u>1,652,275</u>
<b>Total assets</b>		<u>14,561,621</u>	<u>20,392,851</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	12	3,093,570	1,768,465
Borrowings	13	-	330,486
Employee benefits		67,448	220,395
Total current liabilities		<u>3,161,018</u>	<u>2,319,346</u>
<b>Non-current liabilities</b>			
Employee benefits		13,431	6,217
Total non-current liabilities		<u>13,431</u>	<u>6,217</u>
<b>Total liabilities</b>		<u>3,174,449</u>	<u>2,325,563</u>
<b>Net assets</b>		<u>11,387,172</u>	<u>18,067,288</u>
<b>Equity</b>			
Issued capital	14	93,888,554	93,270,526
Reserves		1,565,658	2,193,758
Accumulated losses		<u>(84,067,040)</u>	<u>(77,396,996)</u>
<b>Total equity</b>		<u>11,387,172</u>	<u>18,067,288</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Prescient Therapeutics Limited**  
**Consolidated statement of changes in equity**  
**For the year ended 30 June 2025**



	Issued capital \$	Share based payments reserve \$	Share loan plan reserve \$	Accumulated losses \$	Total equity \$
<b>Consolidated</b>					
Balance at 1 July 2023	93,246,404	1,817,747	324,624	(69,313,323)	26,075,452
Loss after income tax expense for the year	-	-	-	(8,238,050)	(8,238,050)
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive loss for the year	-	-	-	(8,238,050)	(8,238,050)
	-	-	-	-	-
<i>Transactions with owners in their capacity as owners:</i>					
Exercise of unlisted options (note 27)	24,122	(5,972)	-	-	18,150
Vesting of share-based payments	-	211,736	-	-	211,736
Lapse or expiry of share options	-	(154,377)	-	154,377	-
Balance at 30 June 2024	93,270,526	1,869,134	324,624	(77,396,996)	18,067,288
<b>Consolidated</b>					
Balance at 1 July 2024	93,270,526	1,869,134	324,624	(77,396,996)	18,067,288
Loss after income tax expense for the year	-	-	-	(7,322,531)	(7,322,531)
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive loss for the year	-	-	-	(7,322,531)	(7,322,531)
<i>Transactions with owners in their capacity as owners:</i>					
Vesting of share-based payments	-	349,011	-	-	349,011
Lapse or expiry of share options	-	(652,487)	-	652,487	-
Recognition of fair value of LFS shares issued in prior period (note 14)	324,624	-	(324,624)	-	-
Recognition of considerations of LFS shares disposed by the former director (note 14)	293,404	-	-	-	293,404
Balance at 30 June 2025	93,888,554	1,565,658	-	(84,067,040)	11,387,172

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

**Prescient Therapeutics Limited**  
**Consolidated statement of cash flows**  
**For the year ended 30 June 2025**



		<b>Consolidated</b>	
	<b>Note</b>	<b>2025</b>	<b>2024</b>
		<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>			
Payments to suppliers and employees		(11,284,551)	(10,526,196)
Interest received		339,157	760,166
R&D tax incentive		3,712,363	2,368,123
Interest paid		(10,478)	-
Net cash used in operating activities	25	(7,243,509)	(7,397,907)
<b>Cash flows from investing activities</b>			
Proceeds from term deposits with maturity longer than 3 months		4,000,000	12,000,000
Net cash from investing activities		4,000,000	12,000,000
<b>Cash flows from financing activities</b>			
Proceeds from exercise of share options		-	18,150
Repayment of borrowings		(330,486)	-
Net cash from/(used in) financing activities		(330,486)	18,150
Net (decrease)/increase in cash and cash equivalents		(3,573,995)	4,620,243
Cash and cash equivalents at the beginning of the financial year		10,493,183	5,895,430
Effects of exchange rate changes on cash and cash equivalents		(12,384)	(22,490)
Cash and cash equivalents at the end of the financial year	6	<u>6,906,804</u>	<u>10,493,183</u>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

## **1. General information**

The financial statements cover Prescient Therapeutics Limited as a consolidated entity consisting of Prescient Therapeutics Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Prescient Therapeutics Limited's functional and presentation currency.

Prescient Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 2, Level 11, 385 Bourke Street  
Melbourne, VIC, 3000

A description of the nature of the Consolidated entity's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 20 August 2025.

## **2. Material accounting policy information**

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

### **Basis of preparation**

The financial statements have been prepared in accordance with 'Accounting Standards (including Australian Accounting Interpretations)' issued by the Australian Accounting Standards Board and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

The financial statements are presented in Australian dollars, which is also the consolidated entity's functional currency.

### **Investments and other financial assets**

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless an accounting mismatch is being avoided.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the Consolidated entity has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

#### *Financial assets at amortised cost*

A financial asset is measured at amortised cost only if both of the following conditions are met: (i) it is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (ii) the contractual terms of the financial asset represent contractual cash flows that are solely payments of principal and interest.

#### *Financial assets at fair value through profit or loss*

Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii) designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss.

#### *Impairment of financial assets*

The Consolidated entity recognises a loss allowance for expected credit losses on financial assets which are either measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance depends upon the Consolidated entity's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain.

## 2. Material accounting policy information (continued)

Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.

For financial assets mandatorily measured at fair value through other comprehensive income, the loss allowance is recognised in other comprehensive income with a corresponding expense through profit or loss. In all other cases, the loss allowance reduces the asset's carrying value with a corresponding expense through profit or loss.

### Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to the asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

## 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

### *Research and development*

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the consolidated entity is able to use or sell the asset; the consolidated entity has sufficient resources; and intend to complete the development and its costs can be measured reliably. Capitalised development costs are amortised on a straight-line basis over the period of their expected benefit.

### *Research and Development Rebate*

With the successful track record of the consolidated entity in obtaining the Research and Development rebate from the ATO, the estimated 2025 rebate of \$4,356,397 has been accrued into income for the year ended 30 June 2025 (2024: \$3,712,364).

The consolidated entity is entitled to claim grant credits from the Australian Government in recompense for its research and development program expenditure. The program is overseen by AusIndustry, which is entitled to audit and/or review claim lodged for the past 4 years. In the event of a negative finding from such an audit or review AusIndustry has the right to rescind and clawback those prior claims, potentially with penalties. Such a finding may only occur in the event that those expenditures do not appropriately qualify for the grant program. In their estimation, considering also the independent external expertise they have contracted to draft and claim such expenditures, the directors of the company consider that such a negative review has a remote likelihood of occurring.

### *Indefinite life intangible assets*

The consolidated entity tests annually, or more frequently if events or changes in circumstances indicate impairment, whether indefinite life intangible assets have suffered any impairment, in accordance with the accounting policy stated in note 11.

### 3. Critical accounting judgements, estimates and assumptions (continued)

#### *Recovery of deferred tax assets*

Deferred tax assets are recognised for deductible temporary differences only if the consolidated entity considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses. The consolidated entity did not recognise any deferred assets based on its current assessment of the availability of the future taxable amount.

### 4. Operating segments

#### *Identification of reportable operating segments*

The company operated predominately in the clinical stage oncology industry within Australia. AASB 8 requires operating segments to be identified on the basis of internal reports about the components of the consolidated entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The Board reviews the Company as a whole in the business segment of clinical stage oncology within Australia.

#### *Accounting policy for operating segments*

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

### 5. Other income

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Research and development tax incentive	<u>4,356,397</u>	<u>3,712,364</u>

The Research and Development Tax Incentive programme provides tax offsets for expenditure on eligible Research and Development (R&D) activities. Under the programme, Prescient, having expected aggregated annual turnover of under \$20 million, is entitled to a refundable R&D credit of 48.5% (2024: 48.5%) on the eligible R&D expenditure incurred on eligible R&D activities. One of the conditions the company must meet is ensuring more than 50% of total R&D activity costs will be incurred in Australia.

The refundable R&D tax offset is accounted for under AASB 120 Accounting for Government Grants and Disclosure of Government Assistance.

#### *Accounting policy for Government grants*

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

### 6. Cash and cash equivalents

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Cash at bank	6,906,804	4,493,183
Cash on deposit	-	6,000,000
	<u>6,906,804</u>	<u>10,493,183</u>

Cash at bank earns interest at floating rates based on daily bank deposit rates.

Cash on deposit relates to short-term deposits with a maturity of three months or less.



## 7. Trade and other receivables

	Consolidated	
	2025	2024
	\$	\$
<i>Current assets</i>		
GST receivables	263,323	147,625
Other receivables	972	59,007
	<u>264,295</u>	<u>206,632</u>

### *Accounting policy for trade and other receivables*

Trade and other receivables are measured at amortised cost using the effective interest method, less any provision for impairment.

### *Impairment*

Allowances for impairment are recognised using an 'expected credit loss' ('ECL') model. Impairment is measured using a 12-month ECL method unless the credit risk on a financial instrument has increased significantly since initial recognition in which case the lifetime ECL method is adopted.

## 8. Amount due under loan funded share arrangement

	Consolidated	
	2025	2024
	\$	\$
<i>Current assets</i>		
Amount due from former director *	<u>293,404</u>	<u>-</u>

\* During the year ended 30 June 2025, and following the resignation of Steven Yatomi-Clarke ("the former director") on 19 January 2025, 6,000,000 shares under LFS were subsequently disposed of for a total consideration of \$293,404. Under LFS arrangement, the former director was liable to pay the lesser of the original loan balance of \$928,000 or the amount realised on sale of the shares. The value of the shares disposed of \$293,404 were determined by observed market based pricing based on the disposal dates, this being lower amount as per the terms of the LFS. As at 30 June 2025, the outstanding balance was recognised in the statement of financial position as an amount due from former director, with no specific payment term and interest free. In assessing the credit risk in relation to the receivable amount, the company consider the amount to be fully recovered within 12 months.

Refer to note 21 for details of related party transactions and note 27 in relation to share loan plan.

## 9. Other financial assets

	Consolidated	
	2025	2024
	\$	\$
<i>Current assets</i>		
Cash on deposits	20,000	20,000
Term deposits with maturity longer than 3 months	-	4,000,000
	<u>20,000</u>	<u>4,020,000</u>

Cash on deposits are made for varying periods up to twelve months, depending on the immediate cash requirements of the consolidated entity, and earn interest at the respective term deposit rates.

As at 30 June 2025, no term deposits were held. Term deposits held as at 30 June 2024, with maturity terms ranging from 4 to 6 months and interest rates between 4.00% and 4.70% at acquisition, were classified as short-term investments in the statement of financial position in accordance with AASB 107 Statement of Cash Flows.

## 10. Prepayments

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Prepayment - research and development	785,344	-
Prepayment - others	277,806	308,397
	<u>1,063,150</u>	<u>308,397</u>

## 11. Intangibles

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Intellectual property - at cost on acquisition	1,650,176	3,366,894
Less: Impairment loss being write off of asset	-	(1,716,718)
	<u>1,650,176</u>	<u>1,650,176</u>

### Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

<b>Consolidated</b>	<b>Intellectual Property</b>
	<b>\$</b>
Opening Balance at 1 July 2023	3,366,894
Write-off of intangible assets	(1,716,718)
Balance at 30 June 2024	<u>1,650,176</u>
Closing Balance at 30 June 2025	<u>1,650,176</u>

### Accounting policy for intangible assets

Intangible assets acquired separately are initially recognised at cost. Intangible assets with indefinite useful lives or with finite lives however not available for use, are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

The intellectual property has an indefinite useful life.

### Impairment assessment at 30 June 2025

As at 30 June 2025, there were no indicators of impairment in relation to PTX-100 intellectual property, with the group continuing to invest in the development of this technology and having an long-term patent life.

## 11. Intangibles (continued)

The Company applied the cost approach in determining the recoverable amount. A cost approach reflects the amount that would be required to replace the service capacity of an asset (often referred to as current replacement cost).

The key assumptions used to determine the elements of cost included in this model were the initial costs to acquire the asset (licence) and the costs expensed in relation to continuing to advance the progress in the development of these assets. The costs incurred in continuing development were determined in reference to the historical Research and Development claims submitted from 2015 – present.

The fair value is based on level 3 unobservable inputs, being the consolidated entity's internal financial information.

No reasonably possible change in any of the assumptions applied in deriving these recoverable value assessments would have resulted in impairment for the year ended 30 June 2025 in relation to PTX-100 intellectual property of \$1,650,176.

## 12. Trade and other payables

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Trade payables	3,041,154	1,722,203
Other payables and accruals	52,416	46,262
	<u>3,093,570</u>	<u>1,768,465</u>

Refer to note 16 for further information on financial instruments.

## 13. Borrowings

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Borrowings - insurance	-	330,486

Refer to note 16 for further information on financial instruments.

During year ended 30 June 2024, the consolidated entity entered into a premium finance arrangement to fund its insurance with an interest rate of 3.09% and repayable by 25 January 2025. This loan is unsecured. As at 30 June 2025, the loan is fully repaid.

### *Accounting policy for borrowings*

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method. Due to the short-term nature of the borrowings, the face value is considered the fair value.

## 14. Issued capital

	<b>Consolidated</b>			
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
	<b>Shares</b>	<b>Shares</b>	<b>\$</b>	<b>\$</b>
Ordinary shares - fully paid	<u>805,319,793</u>	<u>805,319,793</u>	<u>93,888,554</u>	<u>93,270,526</u>

#### 14. Issued capital (continued)

##### *Movements in ordinary share capital*

Details	Date	Shares	Issue price	\$
Balance	1 July 2024	805,319,793		93,270,526
Recognition of considerations of LFS shares disposed by the former director (refer to note 27 for details)		-		293,404
Recognition of fair value of LFS shares issued in prior period (refer to note 27 for details)		-		324,624
Balance	30 June 2025	<u>805,319,793</u>		<u>93,888,554</u>

##### *Ordinary shares*

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

##### *Share buy-back*

There is no current on-market share buy-back.

##### *Capital risk management*

The Consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The Consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment. The Consolidated entity is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The capital risk management policy remains unchanged from the year ended 30 June 2024.

#### 15. Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

#### 16. Financial instruments

##### *Financial risk management objectives*

The consolidated entity's principal financial instruments comprise receivables, payables, cash at bank and short term deposits from time to time.

The consolidated entity manages its exposures to key financial risk, including interest rate and currencies in accordance with the consolidated entity's financial risk management policy, which requires it to undertake those actions that are necessary to reduce the consolidated entity's exposure to financial risk so as to provide reasonable assurances as to financial outcomes in respect to the transactional circumstances of each situation.

## 16. Financial instruments (continued)

### Market risk

#### Foreign currency risk

The Consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The carrying amount of the Consolidated entity's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	Assets		Liabilities	
	2025 \$	2024 \$	2025 \$	2024 \$
<b>Consolidated</b>				
US dollars	172,977	52,477	568,329	1,109,753

The consolidated entity had net liabilities denominated in foreign currencies of \$395,352 (2024: net liabilities of \$1,057,276). Based on this exposure, the following sensitivity analysis has been performed. The percentage change is the expected overall volatility of the significant currencies, which is based on management's assessment of reasonable possible fluctuations taking into consideration movements over the last 12 months each year and the spot rate at each reporting date.

Consolidated - 2025	% change	AUD strengthened Effect on		% change	AUD weakened Effect on	
		profit before tax	Effect on equity		profit before tax	Effect on equity
US dollars	10%	39,535	39,535	(10%)	(39,535)	(39,535)

Consolidated - 2024	% change	AUD strengthened Effect on		% change	AUD weakened Effect on	
		profit before tax	Effect on equity		profit before tax	Effect on equity
US dollars	10%	105,728	105,728	(10%)	(105,728)	(105,728)

### Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements.

#### Cash and cash equivalents and term deposits

The cash and cash equivalents and term deposits are held with an Australian major bank in accordance with the Board's risk policy. The Board believes the consolidated entity is not exposed to significant credit risk.

### Liquidity risk

The consolidated entity's exposure to the availability of the funds to settle its creditors and other liabilities. The consolidated entity has historically raised capital approximately every 12-18 months.

## 16. Financial instruments (continued)

### Remaining contractual maturities

The following tables detail the consolidated entity's remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

	Weighted average interest rate %	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
<b>Consolidated - 2025</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-	3,041,154	-	-	-	3,041,154
Other payables	-	52,416	-	-	-	52,416
Total non-derivatives		3,093,570	-	-	-	3,093,570
<b>Consolidated - 2024</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-	1,722,203	-	-	-	1,722,203
	-	46,262	-	-	-	46,262
<i>Interest-bearing - fixed rate</i>						
Premium finance	3.09%	330,486	-	-	-	330,486
Total non-derivatives		2,098,951	-	-	-	2,098,951

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

The carrying amount of financial assets and liabilities is a reasonable approximation of fair value.

### Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

## 17. Key management personnel disclosures

### Directors

The following persons were Directors of Prescient Therapeutics Limited during the financial year:

Dr James Campbell *	Non-Executive Chair – Appointed 30 March 2025, was a Non-Executive Director until this date.
Dr Allen Ebens	Non-executive Director
Dr Ellen Feigal	Non-executive Director
Dr Gavin Shepherd	Non-Executive Director – Appointed on 4 July 2024
Ms Melanie Farris	Non-Executive Director – Appointed 10 April 2025
Mr Steven Yatomi-Clarke	Managing Director and CEO – Resigned on 19 January 2025
Mr Steven Engle	Non-executive Chair – Retired on 30 March 2025

\* Dr Campbell received his remuneration through Barrabool Biotechnology Pty Ltd (an entity associated with him).

## 17. Key management personnel disclosures (continued)

### *Other key management personnel*

The following person also had the authority and responsibility for planning, directing and controlling the major activities of the Consolidated entity, directly or indirectly, during the financial year:

Mr James McDonnell

Chief Executive Officer - Appointed 20 January 2025

### *Compensation*

As detailed in the remuneration report (audited) in the Directors' Report, the aggregate compensation to Directors and other members of key management personnel of the Consolidated entity is set out below:

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Short-term employee benefits	922,162	860,082
Post-employment benefits	44,002	42,844
Long-term benefits	61,883	10,925
Share-based payments	199,117	56,543
	<u>1,227,164</u>	<u>970,394</u>

## 18. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by the auditor of the Company:

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<i>Audit services - William Buck</i>		
Audit and half year review of the financial statements	<u>46,765</u>	<u>42,935</u>

## 19. Contingent liabilities and commercial agreements that may impact future operations

The consolidated entity has entered into several agreements whereby it is obliged to make royalty payments on future sales and make future cash milestone payments if certain events occur. These agreements include the following:

### *Yale University - PTX 100*

The agreement includes:

- Milestone payments based on dosing of patients in trials
- Milestone payments based on First New Drug Application (NDA) for a licensed product, and the associated FDA approval of the NDA
- Milestone payments based on market entry of licensed products in certain countries
- Royalty payments based on worldwide annual net sales

### *University of Pennsylvania - OmniCAR*

The agreement includes:

- Development milestone payments based on first dosing of a subject in phases of clinical trials
- Milestone payments based on reaching certain levels of product net sales
- Royalties paid on levels of annual product net sales

### *Oxford University - OmniCAR*

The agreement includes:

## 19. Contingent liabilities and commercial agreements that may impact future operations (continued)

- Royalties paid on net sales of a licensed product
- Milestone payments based on commencement of phases and first regulatory approval of products

### *Moffitt Cancer Center – CellPryme-A*

Prescient licensed intellectual property to complement and strengthen its own intellectual property for CellPryme-A. The agreement includes:

- Royalties paid on net sales of a licensed product
- Milestone payments based on commencement of phases and first regulatory approval of products

## 20. Commitments

The consolidated entity has entered into a number of licence agreements as outlined below:

### *Yale University License agreement - PTX 100*

An agreement was entered into to license certain intellectual property and technology from Yale University. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *University of Pennsylvania License agreement - OmniCAR*

An agreement was entered into to license certain intellectual property and technology from University of Pennsylvania. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *Oxford University License agreement - OmniCAR*

An agreement was entered into to license certain intellectual property and technology from Oxford University. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *Moffitt Cancer Center License agreement – CellPryme-A*

An agreement was entered into to license certain intellectual property and technology from Moffitt Cancer Center. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

## 21. Related party transactions

### *Parent entity*

Prescient Therapeutics Limited is the parent entity.

### *Subsidiaries*

Interests in subsidiaries are set out in note 23.

### *Key management personnel*

Disclosures relating to key management personnel are set out in note 17 and the remuneration report included in the Directors' report.

### *Receivable from and payable to related parties*

There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

### *Loans to/from related parties*

#### *Other transactions with key management personnel and their related parties*

During the year ended 30 June 2025 6,000,000 shares under a Shareholder-approved Loan Funded Share (LFS) arrangement were disposed with the consideration of \$293,404 which is outstanding as at 30 June 2025.

### *Terms and conditions*

All transactions were made on normal commercial terms and conditions and at market rates.



## 22. Parent entity information

Set out below is the supplementary information about the parent entity.

### *Statement of profit or loss and other comprehensive income*

	Parent	
	2025	2024
	\$	\$
Loss after income tax	(7,322,531)	(8,238,050)
Total comprehensive loss	(7,322,531)	(8,238,050)

### *Statement of financial position*

	Parent	
	2025	2024
	\$	\$
Total current assets	12,904,050	18,740,576
Total assets	14,561,621	20,392,851
Total current liabilities	3,161,018	2,319,346
Total liabilities	3,174,449	2,325,563
Equity		
Issued capital	93,888,554	93,270,526
Share based payments reserve	1,565,658	1,869,134
Share loan plan reserve	-	324,624
Accumulated losses	(84,067,040)	(77,396,996)
Total equity	11,387,172	18,067,288

### *Guarantees entered into by the parent entity in relation to the debts of its subsidiaries*

The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2025 (2024: nil).

### *Contingent liabilities*

The parent entity had no contingent liabilities as at 30 June 2025 (2024: nil).

### *Capital commitments - Property, plant and equipment*

The parent entity had no capital commitments for property, plant and equipment at as 30 June 2025 (2024: nil).

### *Material accounting policy information*

The accounting policies of the parent entity are consistent with those of the Consolidated entity, as disclosed in note 2, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.

## 23. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

Name	Principal place of business / Country of incorporation	Ownership interest	
		2025 %	2024 %
OmniCAR Bio Pty Ltd	Australia	100.00%	100.00%
Pathway Oncology Pty Ltd	Australia	100.00%	100.00%
AKTivate Therapeutics Pty Ltd	Australia	100.00%	100.00%

## 24. Events after the reporting period

On 31 July 2025, the Company announced that 74,462,500 ordinary shares to be sophisticated and professional investors at \$0.04 per share under a Placement to raise \$3,000,000 (before costs).

On 4 August 2025, the Company issued 171,732,250 ordinary shares at \$0.04 (4 cents) per share and raised \$6.8 million (before costs) upon completion of Share Purchase Plan ("SPP") on 29 July 2025.

No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Consolidated entity's operations, the results of those operations, or the Consolidated entity's state of affairs in future financial years.

## 25. Reconciliation of loss after income tax to net cash used in operating activities

	Consolidated	
	2025 \$	2024 \$
Loss after income tax expense for the year	(7,322,531)	(8,238,050)
Adjustments for:		
Impairment of intangibles	-	1,716,718
Share-based payments	349,011	211,736
Foreign exchange differences	12,384	22,491
Depreciation	(5,296)	717
Change in operating assets and liabilities:		
(Increase)/(Increase)/decrease in trade and other receivables	(52,693)	3,126
Increase prepayments	(424,266)	(62,089)
(Increase)/Decrease in R&D tax incentive receivable	590,448	(1,344,241)
(Decrease)/ increase in trade and other payables	85,653	(56,201)
(Decrease)/Increase/(decrease) in borrowings	(330,486)	330,486
Increase/(decrease) in employee benefits	(145,733)	17,400
Net cash used in operating activities	<u>(7,243,509)</u>	<u>(7,397,907)</u>

## 26. Earnings per share

	Consolidated	
	2025 \$	2024 \$
Loss after income tax attributable to the Owners of Prescient Therapeutics Limited	<u>(7,322,531)</u>	<u>(8,238,050)</u>

## 26. Earnings per share (continued)

	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	805,311,323	805,311,323
Weighted average number of ordinary shares used in calculating diluted earnings per share	805,311,323	805,311,323
	Cents	Cents
Basic losses per share	(0.91)	(1.02)
Diluted losses per share	(0.91)	(1.02)

The rights to options held by option holders and the holders of performance rights have not been included in the weighted average number of ordinary shares for the purposes of calculating diluted EPS as they do not meet the requirements for inclusion in AASB 133 "Earnings per Share".

## 27. Share-based payments

### Options

Under the company's Employee/Executive Share Option Plan (ESOP), awards are delivered to directors, other key management personnel and employees in the form of options over shares which vest over a period of two to four years, and are not issued to investors as part of capital raising activities. The vesting conditions of the current options on issue are based on time-based milestones.

Set out below are summaries of equity-settled unlisted options granted and on issue at the end of the financial year:

2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired / Forfeited	Balance at the end of the year
10/12/2020	23/11/2024	\$0.0968	17,000,000	-	-	(17,000,000)	-
10/12/2020	08/12/2025	\$0.0968	3,000,000	-	-	-	3,000,000
21/12/2020	21/12/2024	\$0.0923	1,000,000	-	-	(1,000,000)	-
31/05/2021	31/05/2026	\$0.3580	4,000,000	-	-	-	4,000,000
07/07/2021	07/07/2025	\$0.3630	1,950,000	-	-	-	1,950,000
09/07/2021	08/07/2025	\$0.3710	1,000,000	-	-	-	1,000,000
18/10/2021	17/10/2026	\$0.4120	200,000	-	-	-	200,000
21/10/2021	20/10/2026	\$0.4120	200,000	-	-	-	200,000
22/10/2021	21/10/2026	\$0.4120	200,000	-	-	-	200,000
29/10/2021	28/10/2026	\$0.4120	200,000	-	-	-	200,000
03/11/2021	02/11/2026	\$0.4120	200,000	-	-	-	200,000
11/05/2023	09/05/2027	\$0.1309	1,415,000	-	-	-	1,415,000
11/12/2024	11/12/2028	\$0.0621	-	1,415,000	-	-	1,415,000
20/01/2025	20/11/2030	\$0.0812	-	24,000,000	-	-	24,000,000
			30,365,000	25,415,000	-	(18,000,000)	37,780,000
Weighted average exercise price			\$0.1771	\$0.0801	\$0.0000	\$0.0965	\$0.1438

## 27. Share-based payments (continued)

2024

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired / Forfeited	Balance at the end of the year
01/06/2020	01/06/2024	\$0.0750	415,000	-	-	(415,000)	-
10/12/2020	23/11/2024	\$0.0968	17,000,000	-	-	-	17,000,000
10/12/2020	08/12/2025	\$0.0968	4,000,000	-	-	(4,000,000)	-
16/12/2020	21/12/2024	\$0.3630	1,000,000	-	-	-	1,000,000
21/12/2020	21/12/2024	\$0.0923	1,000,000	-	-	-	1,000,000
31/05/2021	31/05/2026	\$0.3580	4,000,000	-	-	-	4,000,000
26/06/2021	26/06/2025	\$0.3630	1,000,000	-	(50,000)	-	950,000
09/07/2021	08/07/2025	\$0.3710	1,000,000	-	-	-	1,000,000
18/10/2021	17/10/2026	\$0.4120	200,000	-	-	-	200,000
21/10/2021	20/10/2026	\$0.4120	200,000	-	-	-	200,000
22/10/2021	21/10/2026	\$0.4120	200,000	-	-	-	200,000
29/10/2021	28/10/2026	\$0.4120	200,000	-	-	-	200,000
03/11/2021	02/11/2026	\$0.4120	200,000	-	-	-	200,000
11/05/2023	09/05/2027	\$0.1309	1,415,000	-	-	-	1,415,000
			31,830,000	-	(50,000)	(4,415,000)	27,365,000

Weighted average exercise price	\$0.1660	\$0.0000	\$0.3630	\$0.0948	\$0.1771
---------------------------------	----------	----------	----------	----------	----------

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
11/12/2024	11/12/2028	\$0.0420	\$0.0621	94.730%	-	3.934%	\$0.025
20/01/2025	20/01/2030	\$0.0500	\$0.0812	89.840%	-	4.210%	\$0.030

\* The above options were fair valued using the Black Scholes option pricing model using the above inputs.

\*\* 1,415,000 unlisted options granted to Gavin Shepherd on 11 December 2024. 25% options to vest immediately, 25% to vest 12 months following the issue date, 25% to vest 24 months following the issue date, and 25% to vest 36 months following the issue date.

\*\*\* 24,000,000 unlisted options granted to James McDonnell on 20 January 2025. The Options will vest annually in four equal tranches from 12 months from the Grant Date until the date that is 48 months from the Grant Date. Vesting of each tranche is subject to the Eligible Participant remaining employed by the Company at the time of the relevant vesting date.

The weighted average remaining contractual life of options outstanding at the end of the financial year was 3.79 year (2024: 1.82 years).

## 27. Share-based payments (continued)

### Share loan plan

On 30 November 2016, shareholders approved the Company's proposal to issue up to 8,000,000 Loan Funded Shares (LFS) with an expiry date of 30 November 2021 to the Company's former Managing Director, Mr Steven Yatomi-Clarke, by way of interest-free loan with no fixed loan repayment date and with recourse to the funding provided for the ordinary shares limited to the outstanding amount drawn down. Should there be a shortfall in the ability of the borrower to settle in full the outstanding amount, the Company may not bring legal proceedings to recover the amount. If the employee sells the shares, the loan amount outstanding is payable on the date of receipt of the funds. A total of 6,000,000 shares were issued under LFS in prior years and the remaining 2,000,000 shares expired on 30 November 2021. The issued ordinary shares have full voting rights and the right to receive dividends, noting that any dividends paid on shares excluding franking credits will first be applied to pay outstanding amounts drawn down.

During the year ended 30 June 2025, 6,000,000 shares under LFS were disposed by Mr Steven Yatomi-Clarke for the consideration of \$293,404. The consideration and respective fair value of the LFS of \$617,404 were accounted for as share capital in equity in recognition of the previously issued LFS shares. Following the resignation of Mr Steven Yatomi-Clarke, the loan funded share arrangement expired. No further share based payment expense was incurred during the period in relation to the above transaction.

There were no further shares issued and nil loan funded share balance at 30 June 2025 (30 June 2024: 6,000,000 and \$928,000 respectively).

Reconciliation of share based payments expense recorded in the statement of profit and loss relating to each class of share based payment:

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
Options expense related to directors and employees	<u>349,011</u>	<u>211,736</u>

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest %	Tax residency	Foreign Jurisdiction in which the entity is a resident for tax purposes (according to the law of the foreign jurisdiction)
			%		
Prescient Therapeutics Ltd	Body Corporate	Australia	-	Australia	n/a
OmniCAR Bio Pty Ltd	Body Corporate	Australia	100.00%	Australia	n/a
Pathway Oncology Pty Ltd	Body Corporate	Australia	100.00%	Australia	n/a
AKTivate Therapeutics Pty Ltd	Body Corporate	Australia	100.00%	Australia	n/a

### Basis of preparation

This Consolidated Entity Disclosure Statement (CEDS) has been prepared in accordance with the Corporations Act 2001, reflecting the amendments to section 295(3A)(vi) and (vii) which clarify the definition of foreign resident as being an entity that is treated as a resident of a foreign country under the tax laws of that foreign country. These amendments apply for financial years beginning on or after 1 July 2024. The CEDS includes certain information for each entity that was part of the consolidated entity at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.

### Determination of tax residency

Section 295(3B)(a) of the Corporation Act 2001 defines Australian tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are different interpretations that could be adopted, and which could give rise to a different conclusion on residency. Section 295 (3A)(a)(vii) requires the determination of tax residency in a foreign jurisdiction to be based on the law of the foreign jurisdiction relating to foreign income tax.

In determining tax residency, the Consolidated entity has applied the following interpretations:

#### Australian tax residency

The Consolidated entity has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5.

#### Foreign tax residency

Where necessary, the Consolidated entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with (see section 295(3A)(vii) of the Corporations Act 2001). None of the group entities are foreign tax residents.

#### Partnerships and Trusts

None of the entities noted above were trustees of trusts within the Consolidated entity, partners in a partnership within the Consolidated entity or participants in a joint venture within the Consolidated entity.

In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 of the financial statements;
- the attached financial statements and notes give a true and fair view of the Consolidated entity's financial position as at 30 June 2025 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

A handwritten signature in black ink, appearing to read "J Campbell", written over a horizontal line.

---

Dr James Campbell  
Chair

20 August 2025

## Independent auditor's report to the members of Prescient Therapeutics Limited

### Report on the audit of the financial report



#### Our opinion on the financial report

In our opinion, the accompanying financial report of Prescient Therapeutics Limited (the Company) and its subsidiaries (the Group) is in accordance with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 30 June 2025 and of its financial performance for the year then ended; and
- complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### What was audited?

We have audited the financial report of the Group, which comprises:

- the consolidated statement of financial position as at 30 June 2025,
- the consolidated statement of profit or loss and other comprehensive income for the year then ended,
- the consolidated statement of changes in equity for the year then ended,
- the consolidated statement of cash flows for the year then ended,
- notes to the financial statements, including material accounting policy information,
- the consolidated entity disclosure statement, and
- the directors' declaration.

### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



## Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

1. Assessment of impairment of intangible assets	Area of focus (refer also to notes 2, 3 & 11)	How our audit addressed the key audit matter
	<p>As at 30 June 2025 and as disclosed in Note 10, the Group continued to record \$1.7m related to intellectual property ('IP') assets being PTX-100 which was acquired in the 2014 calendar year.</p> <p>Since its acquisition, all subsequent research and development costs incurred related to the PTX-100 asset have been classified as research costs in accordance with AASB 138 <i>Intangible Assets</i> and charged as incurred to the profit and loss.</p> <p>Consistent with the prior year, the recoverable value of the PTX-100 was subject to an annual impairment test by applying a replacement cost model.</p> <p>In assessing this fair value, the Directors considered the following sources of information to assessment impairment, being:</p> <ul style="list-style-type: none"> <li>— The replacement value of the IP asset by examining what costs would be necessary to bring its PTX-100 asset to its present condition in replicating all research and development costs contributed to the asset up to 30 June 2025;</li> <li>— The outcomes of PTX-100 clinical trial studies performed in the period; and</li> <li>— Comparing the overall market capitalisation of the Group to its net asset value.</li> </ul>	<p>Our audit procedures included:</p> <ul style="list-style-type: none"> <li>— We obtained and reviewed a copy of management's indicators of impairment assessment paper and management's fair value assumptions for the IP asset;</li> <li>— We re-examined the licence conditions over PTX-100 including the tenure of the patent held by the licence owner noting the ongoing availability of use;</li> <li>— We assessed the reasonableness of variables and inputs used to support the replacement cost fair value in order to determine that the cost is in excess of the IP asset's carrying value;</li> <li>— We reviewed the public disclosures related to the PTX-100 clinical phase trials; and</li> <li>— We re-performed other impairment indication tests including assessment of the Group's market capitalisation, noting the excess over the Group's net assets.</li> </ul> <p>We also assessed the adequacy of the financial statement disclosures in note 11 concerning impairment in these financial statements.</p>

Due to the judgments and estimates applied including market factors in assessing the replacement cost amounts of the IP asset, this was considered a key audit matter.

## Other information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2025, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

- the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the

aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at:

[https://www.auasb.gov.au/media/bwvjcgre/ar1\\_2024.pdf](https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf)

This description forms part of our auditor's report.

## Report on the Remuneration Report



### Our opinion on the Remuneration Report

In our opinion, the Remuneration Report of Prescient Therapeutics Limited, for the year ended 30 June 2025, complies with section 300A of the *Corporations Act 2001*.

### What was audited?

We have audited the Remuneration Report included in pages 13 to 19 of the directors' report for the year ended 30 June 2025.

## Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

William Buck

**William Buck Audit (Vic) Pty Ltd**  
ABN 59 116 151 136

**R. P. Burt**

Director

Melbourne, 20 August 2025

The shareholder information set out below was applicable as at 31 July 2025. Currently there is no on-market buy-back of the Company's securities.

### Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

	Ordinary shares	
	Number of holders	% of total shares issued
1 to 1,000	2,528	0.03
1,001 to 5,000	660	0.28
5,001 to 10,000	708	0.71
10,001 to 100,000	2,718	13.62
100,001 and over	1,281	85.37
	<b>7,895</b>	<b>100.00</b>
Holding less than a marketable parcel	<b>3,943</b>	<b>1.07</b>

### Equity security holders

*Twenty largest quoted equity security holders*

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares issued
MR DAVID KENLEY	18,500,000	2.30
BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	11,317,595	1.41
DR GAVIN JAMES SHEPHERD & MRS CATHERINE SHEPHERD <TPJ SUPERANNUATION FUND A/C>	10,500,000	1.30
CITICORP NOMINEES PTY LIMITED	9,874,402	1.23
MR ANDREW MORRISON STEWART	8,756,176	1.09
MR ANTHONY SHANE KITTEL & MRS MICHELE THERESE KITTEL <KITTEL FAMILY SUPER A/C>	7,550,000	0.94
MR CLINTON CRAIG HOPPER	7,400,000	0.92
BNP PARIBAS NOMS PTY LTD	7,150,405	0.89
NETWEALTH INVESTMENTS LIMITED <SUPER SERVICES A/C>	7,100,008	0.88
MR RICHARD THOMAS HAYWARD DALY & MRS SARAH KAY DALY <THE DALY FAMILY SUPER A/C>	7,000,000	0.87
GAVNCATH PTY LTD <SHEPHERD INVESTMENT A/C>	6,500,000	0.81
DR ROSAMUND JULIAN BANYARD & MR PHILLIP STANLEY HOLTEN <R BANYARD SUPER FUND A/C>	6,205,525	0.77
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	6,128,744	0.76
BOYCECORP PTY LTD <BOYCECORP DISCRETIONARY A/C>	5,809,400	0.72
SB INVESTMENTS PTY LTD <BROADLEY UNIT A/C>	5,653,928	0.70
MR JAKOV KULIS	5,297,989	0.66
DOSSMAN PTY LTD	4,682,077	0.58
MR ANTHONY GRAEME HALLS & MRS SIMONE JUSTINE HALLS <ELLALILY SUPERFUND A/C>	4,200,000	0.52
DR VINCENT WILLIAM FITZGERALD & MRS PENELOPE FITZGERALD <FITZGERALD SUPER FUND A/C>	4,080,518	0.51
NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C>	3,918,223	0.49
	<b>147,624,990</b>	<b>18.33</b>

*Unquoted equity securities*

	Number on issue	Number of holders
Options over ordinary shares issued	34,830,000	10

**Substantial holders**

The Company has received no substantial Shareholder notices as at the date of this report.

**Voting rights**

The voting rights attached to ordinary shares are set out below:

*Ordinary shares*

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

**Corporate Governance Statement**

The Company's 2025 Corporate Governance Statement has been released to ASX on the date this Annual Report is first published and is available on the Company's website at: <https://prescienttherapeutics.investorportal.com.au>

**Annual General Meeting and Director Nomination**

Prescient Therapeutics Limited advises that its Annual General Meeting (AGM) will be held on or about Tuesday, 14 October 2025. The time and other details relating to the meeting will be advised in the Notice of Meeting (NoM) to be sent to all Shareholders and released to ASX immediately upon despatch.

The Closing date for receipt of nomination for the position of Director is Thursday, 29 August 2025. Any nominations must be received in writing no later than 5.00pm (Melbourne time) on Thursday, 29 August 2025 at the Company's Registered Office. The Company notes that the deadline for nominations for the position of Director is separate to voting on Director elections. Details of the Director's to be elected will be provided in the Company's Notice of AGM in due course.